supplier
Organon Pharmaceuticals UK Ltd
Organon Pharmaceuticals UK Ltd has won 35 UK public sector awards from 4 buyers since 2021. The typical award is worth £469,741,518.
as a supplier
35 recorded awards from 4 buyers , between 18 Aug 2021 and 30 Jun 2025.
“Exclusive” means this organisation was the only one awarded under that procurement; the rest were shared with other suppliers, typically on a framework.
sells to
| buyer | awards |
|---|---|
| NHS England | 30 |
| Atamis Ltd | 2 |
| The NHS Commissioning Board (operating under the name of NHS England) | 2 |
| eTenderwales | 1 |
common questions about Organon Pharmaceuticals UK Ltd
How many public sector contracts has Organon Pharmaceuticals UK Ltd won?
- Organon Pharmaceuticals UK Ltd has won 35 UK public sector contracts from 4 public bodies since 2021.
Which public bodies buy from Organon Pharmaceuticals UK Ltd?
- Organon Pharmaceuticals UK Ltd has won the most contracts from NHS England, Atamis Ltd and The NHS Commissioning Board (operating under the name of NHS England).
How large are Organon Pharmaceuticals UK Ltd's contracts?
- The median published value of a contract won by Organon Pharmaceuticals UK Ltd is £469,741,518. Framework ceilings are excluded, because they state a spending limit shared across many suppliers rather than a value one supplier received.
Which Organon Pharmaceuticals UK Ltd contracts are expiring soon?
- 4 contracts involving Organon Pharmaceuticals UK Ltd have end dates in the next 12 months, the earliest on 31 May 2027.
contracts expiring in the next 12 months
Contract end dates as published on the original notice. An end date is not a commitment to re-tender — a contract may be extended, varied or allowed to lapse — but it is the earliest public signal that work may come back to market.
| contract | counterparty | value | ends |
|---|---|---|---|
| NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1) | NHS England | £1 | 31 May 2027 |
| NHS National Generic Pharmaceuticals Wave 14c | NHS England | · | 31 May 2027 |
| NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | £986,282,758 | 31 Aug 2027 |
| NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | NHS England | · | 31 Aug 2027 |
contracts won
every contract won by Organon Pharmaceuticals UK Ltd →
where these figures come from
Every figure on this page is derived from notices published by Contracts Finder, Find a Tender, Public Contracts Scotland and Sell2Wales, under the Open Government Licence v3.0. The corpus runs from 17 Dec 2014 to 11 Sept 2026 and is refreshed from the publishers' own APIs through the working day.
Records are combined into one organisation on identifiers where publishers provide them — a Companies House number, a GB-PPON supplier id — and on exact normalised name and address where they do not. Never on address alone: one shared-service postcode carries 244 unrelated organisations.
Counts are of contracting processes, not published notices: a tender and its award notice are one contract, and are counted once. Values are medians, never totals, and exclude framework ceilings — a ceiling states a spending limit shared across every supplier on the framework, so adding them together produces a number no one ever spent. sources and coverage · how matching works
Contains public sector information licensed under the Open Government Licence v3.0.